HARP - HARP Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Harpoon Therapeutics to Merck | Benzinga
MONSEY, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $23.00 per share in cash pursuant to which Harpoon Therapeutics, Inc. (NASDAQ:HARP) ("Harpoon") has agreed to be sold to Merck & Co., Inc. ("Merck"). The sales price is below the price target of $30.00 per share of Wall Street analyst William Maughan at Canaccord Genuity.
If you remain a Harpoon shareholder and question the fairness of the price, you may contact our firm at the following link to discuss your legal rights at no charge:
https://wohlfruchter.com/cases/harpoon-therapeutics/
Alternatively, you may contact us by phone at ...